Cardiol Therapeutics (CRDL) vs Protara Therapeutics (TARA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cardiol Therapeutics (CRDL) has outperformed Protara Therapeutics (TARA) over the past year, gaining 20.4% versus a loss of 47.7%. Over five years, TARA leads with a -61.3% price change compared with -66.9% for CRDL. Protara Therapeutics is the larger company by market cap ($160.7 million vs $154.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRDL | TARA |
|---|---|---|
| Share price | $1.27 | $2.72 |
| Market cap | $154.32M | $160.74M |
| 1-day change | -2.30% | +2.65% |
| YTD return | +36.27% | -50.28% |
| 1-year return | +20.37% | -47.73% |
| 5-year return | -66.92% | -61.26% |
| EPS (TTM) | $-0.25 | $-1.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.34 | $7.82 |
| 52-week low | $0.88 | $2.51 |
| Distance from 52-week high | -45.73% | -65.22% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +558.27% | +845.22% |
| Average volume | 1.45M | 814.80K |
| Shares outstanding | 121.51M | 59.10M |
| Employees | 18 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRDL has outperformed TARA by 68.1 percentage points over the past year.
About Cardiol Therapeutics
CRDL stock →Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
About Protara Therapeutics
TARA stock →Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
CRDL vs TARA FAQ
Which is bigger, Cardiol Therapeutics or Protara Therapeutics?
Protara Therapeutics (TARA) is larger, with a market capitalization of $160.74M compared with $154.32M for Cardiol Therapeutics (CRDL).
Which stock has performed better over the past year, CRDL or TARA?
CRDL returned +20.37% over the past 12 months, compared with -47.73% for TARA (price return, excluding dividends). Past performance does not predict future results.
Are Cardiol Therapeutics and Protara Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.